SARS-CoV
SARS coronavirus
SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).
CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.
All Product Categories
-
SARS-CoV Related Products (1200)
Related Products (1200)
-
Recombinant Proteins (196)
-
SARS-CoV-2 nsp3-IN-3
0 ImagesCat. No.: HY-187379CAS No.: 3118016-51-3SARS-CoV-2 nsp3-IN-3 is a SARS-CoV-2 Nsp3 macrodomain (Mac1) inhibitor with an IC50 value of 7.24 μM that is inactive against Mac1 hydrolytic activity at concentrations up to 1 mM. SARS-CoV-2 nsp3-IN-3 can be used for the research of covid-19.
-
SARS-CoV-2 PLpro-IN-3
0 ImagesCat. No.: HY-179293SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC50 = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7). The EC50 of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations.
-
CG-0988
0 ImagesCat. No.: HY-183752CAS No.: 3069291-10-4CG-0988 is a selective SARS-CoV-2 3C-like protease (3CLpro) inhibitor with an IC50 of 8.5 nM. CG-0988 functionally inhibits SARS-CoV-2 3CLpro, blocks SARS-CoV-2 replication, and exerts antiviral activity against SARS-CoV-2 variants. CG-0988 can be used in research related to coronavirus disease 2019 (COVID-19).
-
(M)-AVI-4773
0 ImagesCat. No.: HY-181033CAS No.: 3111610-68-2
-
Ferrocin A
0 ImagesCat. No.: HY-N14351CAS No.: 114550-08-2Ferrocin A is a lipopeptide compound that targets the SARS-CoV-2 RNA-dependent RNA polymerase (nsp12). Ferrocin A can stably bind to nsp12, and as an iron-chelating peptide, it reduces the concentration of free iron in the environment via complexation, thereby inhibiting bacterial growth by repressing the acquisition of essential metal cations. As an iron-chelating antiviral molecule, Ferrocin A may be used in studies related to COVID-19 and bacterial infections.
-
Corticostatin, human TFA
0 ImagesCat. No.: HY-P10996Synonyms: Human Neutrophil Peptide-4 TFACorticostatin, human (Human Neutrophil Peptide-4) TFA is an antimicrobial peptide with demonstrated antiviral activity. Corticostatin, human TFA can kill Escherichia coli, Streptococcus faecalis, and Candida albicans. Corticostatin, human (HNP-4) TFA is more bactericidal against Gram-negative bacteria than any of HNP-1-3. Corticostatin, human TFA can be isolated from the azurophil granule fraction of discontinuous Percoll gradients.
-
SARS-CoV-2-IN-59
0 ImagesCat. No.: HY-W348072CAS No.: 850786-33-3
-
Ibramvibart
0 ImagesCat. No.: HY-P991170CAS No.: 3031270-42-2
-
SARS-CoV-2 nsp13-IN-6
0 ImagesCat. No.: HY-150632CAS No.: 951588-85-5SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA+ ATPase and ssDNA- ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19.
-
Teicoplanin sodium
0 ImagesCat. No.: HY-A0097ACAS No.: 184539-13-7Synonyms: Antibiotic MDL-507 sodium; MDL-507 sodiumTeicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity.
-
2'-RIBOTAC-U
0 ImagesCat. No.: HY-1625042'-RIBOTAC-U is a ribonuclease (RNase) targeting chimeras (RIBOTACs) and SARS-CoV-2 replication inhibitor. 2'-RIBOTAC-U is composed of a metabolic handle (Blue), a linker (Black) and a RNase L recruiter (Pink). RIBOTACs recruits cellular RNases to specific RNA targets, thereby leading to the degradation of these RNAs.
-
Guineesine
0 ImagesCat. No.: HY-121205CAS No.: 55038-30-7Guineesine can be isolated from Piper longum L.
-
MR1-114
0 ImagesCat. No.: HY-182894MR1-114 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 0.037 μM. As a broad-spectrum inhibitor, MR1-114 maintains submicromolar activity against SARS-CoV-2 Delta, Omicron B.1.1.529 and Omicron BA.5 variants, with EC50 values of 0.18 μM, 0.39 μM and 0.20 μM, respectively. MR1-114 can be used for the research of coronavirus disease 2019 (SARS-CoV-2 infection).
-
SARS-CoV-2 3CLpro-IN-6
0 ImagesCat. No.: HY-152005CAS No.: 302821-53-0SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CLpro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19).
